Literature DB >> 2763505

Analysis of natural killer cells in patients with idiopathic autoimmune hemolytic anemia.

R Conte1, A Dinota, P L Tazzari, D Belletti, G Sermasi.   

Abstract

A functional and phenotypic analysis of the circulating natural killer (NK) cell population was carried out in 9 patients with idiopathic autoimmune hemolytic anemia (IAHA). The NK-cell activity, assessed by a sensitive method based on the inhibition of target clone growth in plasma semisolid medium, was markedly decreased in all patients as compared with normal controls and was not restored by stimulation of the cells with recombinant alpha interferon (alpha-IFN). Analysis of peripheral blood phenotypic markers showed that cells bearing Leu7 and CD16 antigens numbered in the normal range. These findings suggest that IAHA patients exhibit a functional impairment of the NK compartment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2763505     DOI: 10.1111/j.1423-0410.1989.tb02040.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours.

Authors:  Vidyasagar Devaprasad Dedeepiya; Hiroshi Terunuma; Xuewen Deng; Subramani Baskar; Sadananda Rao Manjunath; Rajappa Senthilkumar; Palanisamy Murugan; Paramasivam Thamaraikannan; Thangavelu Srinivasan; Senthilkumar Preethy; Samuel J K Abraham
Journal:  Oncol Lett       Date:  2011-11-29       Impact factor: 2.967

2.  Autologous enhancement by interferon of natural killer activity of human peripheral blood lymphocytes.

Authors:  S B Cheknev; Y G Ashmanova; A D Pritsker; O L Latysheva; F I Yershov; A J Kulberg
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

3.  Proceedings of the Annual Symposium & Plenary Session on Regenerative Medicine (PASRM).

Authors: 
Journal:  J Stem Cells Regen Med       Date:  2012-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.